Active vitamin D treatment in mitigating the onset of sarcopenia among adults with prediabetes
A recent study showed that the use of eldecalcitol may help in preventing the onset of sarcopenia in individuals with prediabetes by enhancing skeletal muscle volume and strength. This study’s findings were published in the Lancet Healthy Longevity.
In this randomised, placebo-controlled, double-blind, multicenter trial, a total of 1094 participants were divided into two groups, with 548 in the eldecalcitol group and 546 in the placebo group. The primary endpoint of the study was the incidence of sarcopenia over a 3-year period in the intention-to-treat population, characterised by weak handgrip strength (<18 kg for women and <28 kg for men) and low appendicular skeletal muscle index (<5·7 kg/m2 for women and <7·0 kg/m2 for men in bioelectrical impedance analysis). Hypercalcaemia was identified as 10·4 mg/dL (2·6 mmol/L) or higher, while a level of 11·0 mg/dL or higher was considered enough to warrant discontinuation of the study.
Eldecalcitol demonstrated a statistically significant preventive effect on the incidence of sarcopenia when compared to the placebo, with 25 participants (4.6%) out of 548 in the eldecalcitol group and 48 participants (8.8%) out of 546 in the placebo group. There was no variance in the occurrence of adverse events between the two groups.
Thus, it can be concluded that eldecalcitol could potentially prevent sarcopenia in individuals with prediabetes by increasing skeletal muscle strength and volume, ultimately reducing the risk of falls
Active vitamin D treatment in mitigating the onset of sarcopenia among adults with prediabetes
A recent study showed that the use of eldecalcitol may help in preventing the onset of sarcopenia in individuals with prediabetes by enhancing skeletal muscle volume and strength. This study’s findings were published in the Lancet Healthy Longevity.
In this randomised, placebo-controlled, double-blind, multicenter trial, a total of 1094 participants were divided into two groups, with 548 in the eldecalcitol group and 546 in the placebo group. The primary endpoint of the study was the incidence of sarcopenia over a 3-year period in the intention-to-treat population, characterised by weak handgrip strength (<18 kg for women and <28 kg for men) and low appendicular skeletal muscle index (<5·7 kg/m2 for women and <7·0 kg/m2 for men in bioelectrical impedance analysis). Hypercalcaemia was identified as 10·4 mg/dL (2·6 mmol/L) or higher, while a level of 11·0 mg/dL or higher was considered enough to warrant discontinuation of the study.
Eldecalcitol demonstrated a statistically significant preventive effect on the incidence of sarcopenia when compared to the placebo, with 25 participants (4.6%) out of 548 in the eldecalcitol group and 48 participants (8.8%) out of 546 in the placebo group. There was no variance in the occurrence of adverse events between the two groups.
Thus, it can be concluded that eldecalcitol could potentially prevent sarcopenia in individuals with prediabetes by increasing skeletal muscle strength and volume, ultimately reducing the risk of falls